Cargando…

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension

BACKGROUND: Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Previous studies in PAH have demonstrated greater treatment benefits in more symp...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, R. James, Vonk-Noordegraaf, Anton, Rosenkranz, Stephan, Oudiz, Ronald J., McLaughlin, Vallerie V., Hoeper, Marius M., Grünig, Ekkehard, Ghofrani, Hossein-Ardeschir, Chakinala, Murali M., Barberà, Joan A., Blair, Christiana, Langley, Jonathan, Frost, Adaani E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739949/ https://www.ncbi.nlm.nih.gov/pubmed/31511080 http://dx.doi.org/10.1186/s12931-019-1180-1

Ejemplares similares

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study
por: Gillies, Hunter, et al.
Publicado: (2023)

Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial
por: Souza, Rogerio, et al.
Publicado: (2023)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study
por: Frantz, Robert P., et al.
Publicado: (2015)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Author rebuttal to response regarding “Letter to the Editor regarding ‘Could pulmonary arterial hypertension patients be at lower risk from severe COVID-19?’”
por: Horn, Evelyn, et al.
Publicado: (2020)

The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension
por: Forfia, Paul, et al.
Publicado: (2023)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry
por: Hoeper, Marius M., et al.
Publicado: (2022)

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension
por: Hoeper, Marius M., et al.
Publicado: (2022)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
por: Coghlan, J Gerry, et al.
Publicado: (2014)

Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
por: Matthews, Jennifer Cowger, et al.
Publicado: (2008)

Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2022)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
por: Pfarr, Nicole, et al.
Publicado: (2011)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic
por: Ryan, John J., et al.
Publicado: (2020)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
por: Hoeper, Marius M., et al.
Publicado: (2015)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Diagnosis of pulmonary hypertension
por: Frost, Adaani, et al.
Publicado: (2019)

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study
por: Konstantinides, Stavros V., et al.
Publicado: (2016)

Riociguat: Clinical research and evolving role in therapy
por: Klinger, James R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qjneaq89kho602neniad8t12g4